参考文献/References:
[1]张瑜,王娟.脓毒症并发急性呼吸窘迫综合征患者血清血管内皮钙黏蛋白、血管生成素2表达及与预后相关性研究[J].陕西医学杂志,2022,51(2):176-179,190.
[2]佘丽萍,王垚,黄敏,等.线粒体自噬受体FUNDC1在脓毒症大鼠心肌损伤中对氧化应激响应的调控[J].陕西医学杂志,2025,54(4):441-446.
[3]赵玉月,钱瑞,李涛,等.白细胞介素-6与可溶性肿瘤抑制因子2对腹腔感染脓毒症患者合并急性呼吸窘迫综合征的诊断意义[J].中国中西医结合急救杂志,2024,31(5):533-537.
[4]兰琪,刘孟楠,伍浩,等.sST2在心血管疾病中的应用价值[J].中国循证心血管医学杂志,2024,16(5):634-636.
[5]WANG X,ZHOU Z,LI D,et al.The molecular mechanisms of imatinib treatment on acute lung injury in septic mice through proteomic technology[J].J Immunol Res,2025,2025:4526375.
[6]CHEN T,XIE Q,TAN B,et al.Inhibition of pyruvate dehydrogenase kinase 4 protects cardiomyocytes from lipopolysaccharide-induced mitochondrial damage by reducing lactate accumulation[J].Inflammation,2024,47(4):1356-1370.
[7]李聪,李丽丽,刘辉.老年脓毒症患者血清SDC-1、CitH3水平表达及临床意义[J].中国医药导报,2023,20(22):92-96.
[8]李玄,林祉均,陈梓欣,等.基于中性粒细胞胞外诱捕网探讨暖心康改善缺血性心力衰竭小鼠心功能的机制[J].中华中医药学刊,2024,42(2):175-178.
[9]SINGER M,DEUTSCHMAN C S,SEYMOUR C W,et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA,2016,315(8):801-810.
[10]李志宇,崔少华,耿立霞.生物标志物联合检测对脓毒性心肌损伤患者早期诊断及预后评估的价值[J].中华危重病急救医学,2021,33(4):443-448.
[11]PULIDO J N,AFESSA B,MASAKI M,et al.Clinical spectrum,frequency,and significance of myocardial dysfunction in severe sepsis and septic shock[J].Mayo Clin Proc,2012,87(7):620-628.
[12]KNAUS W A,DRAPER E A,WAGNER D P,et al.APACHEⅡ:A severity of disease classification system[J].Crit Care Med,1985,13(10):818-829.
[13]FERREIRA F L,BOTA D P,BROSS A,et al.Serial evaluation of the SOFA score to predict outcome in critically ill patients[J].JAMA,2001,286(14):1754-1758.
[14]刘子惠,缪惠洁,张育才.脓毒症心肌病的治疗研究进展[J].中国小儿急救医学,2024,31(10):783-787.
[15]张萌,段美丽,林瑾,等.脓毒症心肌损伤患者的预后影响因素分析[J].临床和实验医学杂志,2020,19(8):846-849.
[16]陶丽丽,魏星,许琪,等.基于后负荷校正的心功能参数建立脓毒症心肌病患者预后的列线图预测模型[J].中华危重病急救医学,2021,33(11):1296-1301.
[17]李心瑶,陈俊,李灼.脓毒症心肌病的发病机制研究进展[J].心血管病学进展,2024,45(1):44-47.
[18]WU Q,ZHENG X,LIN X,et al.Predictive role of serum sST2 for heart failure in children with severe pneumonia[J].Eur J Med Res,2025,30(1):593.
[19]DAVINI F,FOGOLARI M,D’AVANZO G,et al.Soluble suppression of tumorigenicity 2 (sSt2) as a diagnostic and prognostic marker in acute heart failure and sepsis:A comparative analysis[J].Diagnostics (Basel),2025,15(8):1010.
[20]张丽燕,陈洪茂,付兴,等.实时三维超声心动图联合血清NT-proBNP、MR-proADM、sST2对心力衰竭患者诊断及预后的评估价值[J].现代生物医学进展,2024,24(9):1741-1746.
[21]LI X,TIAN Y,CAO H,et al.Serum sST2:Key biomarkers in COVID-19 patients with implications for coronary artery disease[J].BMC Infect Dis,2025,25(1):471.
[22]MENG X,ZHANG K,ZENG W J,et al.Expression and clinical implications of pro-bnp and soluble ST2 in chronic heart failure[J].Br J Hosp Med (Lond),2024,85(12):1-13.
[23]MATYAR S,AIKALIN AKPINAR A,DISEL N R,et al.Prognostic value of sSt2 in long-term mortality in acute heart failure[J].Acta Cardiol,2024,79(8):924-934.
[24]CHEN T,YE L,ZHU J,et al.Inhibition of pyruvate dehydrogenase kinase 4 attenuates myocardial and mitochondrial injury in sepsis-induced cardiomyopathy[J].J Infect Dis,2024,229(4):1178-1188.
[25]YAP J Q,NIKOUEE A,KIM M,et al.Myocardial pyruvate dehydrogenase kinase 4 drives sex-specific cardiac responses to endotoxemia[J].JCI Insight,2025,10(13):e191649.